Top

Published in:

Open Access 01-12-2019 | Original Contribution

Survival of L. casei DG^® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population

Published in: European Journal of Nutrition | Issue 8/2019

Abstract

Purpose

Ability to survive the digestive process is a major factor in determining the effectiveness of a probiotic. In this study, the ability of the probiotic L. casei DG^® (Lactobacillus paracasei CNCMI1572) to survive gastrointestinal transit in healthy children was investigated for the first time.

Methods

Twenty children aged 3–12 years received L. casei DG^® as drinkable solution of 1 × 10⁹ colony forming units (CFU), once daily for 7 consecutive days. Recovery in faecal samples was evaluated at baseline and at different time-points during and after administration. Defecation frequency, faeces consistency, digestive function and product safety were also assessed.

Results

Nineteen (95%) of the 20 enrolled children presented viable L. casei DG^® cells in their faeces at least once during the study, with a maximum count (mean 4.3 log₁₀ CFU/g ± 2.3) reached between day 4 and 6 from the beginning of consumption. Notably, for 11 (57.9%) of the 19 children with viable cells, L. casei DG^® survived in faecal samples up to 3 days after treatment end. Defecation frequency, faeces consistency and digestive function did not change considerably during or after study treatment. Safety of the study product was very good.

Conclusions

This study showed for the first time that L. casei DG^® survives the gastrointestinal transit when ingested by children with a paediatric probiotic drinkable solution containing 1 × 10⁹ CFU, and persists in the gut up to 3 days after the end of product intake, demonstrating resistance to gastric juices, hydrolytic enzymes and bile acids.

Available only for authorised users

FAO and WHO working group (2002) Probiotics in food: health and nutritional properties and guidelines for evaluation. http://www.fao.org/3/a-a0512e.pdf. Accessed 20 Apr 2018

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME (2014) Expert consensus document. The International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11(8):506–514. https://doi.org/10.1038/nrgastro.2014.66 CrossRefPubMed

Saxelin M, Tynkkynen S, Mattila-Sandholm T, de Vos WM (2005) Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol 16(2):204–211. https://doi.org/10.1016/j.copbio.2005.02.003 CrossRefPubMed

Derrien M, van Hylckama Vlieg JET (2015) Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol 23(6):354–366. https://doi.org/10.1016/j.tim.2015.03.002 CrossRefPubMed

Ljungh A, Wadström T (2006) Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol 7(2):73–89PubMed

Guglielmetti S, Mora D, Gschwender M, Popp K (2011) Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. Aliment Pharmacol Ther 33(10):1123–1132. https://doi.org/10.1111/j.1365-2036.2011.04633.x CrossRefPubMed

Shen J, Zuo ZX, Mao AP (2014) Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20(1):21–35. https://doi.org/10.1097/01.MIB.0000437495.30052.be CrossRefPubMed

Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C (2018) A review of probiotic supplementation in healthy adults: helpful or hype? Eur J Clin Nutr. https://doi.org/10.1038/s41430-018-0135-9 CrossRefPubMed

Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N (1995) Symposium: probiotic bacteria for humans: clinical systems for evaluation of effectiveness. J Dairy Sci 78:1597–1606CrossRefPubMed

10.

Perdigón G, Fuller R, Raya R (2001) Lactic acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol 1:27–42

11.

Dommels YE, Kemperman RA, Zebregs YE, Draaisma RB, Jol A, Wolvers DA, Vaughan EE, Albers R (2009) Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. Appl Environ Microbiol 75(19):6198–6204. https://doi.org/10.1128/AEM.01054-09 CrossRefPubMedPubMedCentral

12.

Saxelin M, Lassig A, Karjalainen H, Tynkkynen S, Surakka A, Vapaatalo H, Järvenpää S, Korpela R, Mutanen M, Hatakka K (2010) Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese. Int J Food Microbiol 144(2):293–300. https://doi.org/10.1016/j.ijfoodmicro.2010.10.009 CrossRefPubMed

13.

Hütt P, Kõll P, Stsepetova J, Alvarez B, Mändar R, Krogh-Andersen K, Marcotte H, Hammarström L, Mikelsaar M (2011) Safety and persistence of orally administered human Lactobacillus sp. strains in healthy adults. Benef Microbes 2(1):79–90. https://doi.org/10.3920/BM2010.0023 CrossRefPubMed

14.

Tuohy KM, Pinart-Gilberga M, Jones M, Hoyles L, McCartney AL, Gibson GR (2007) Survivability of a probiotic Lactobacillus casei in the gastrointestinal tract of healthy human volunteers and its impact on the faecal microflora. J Appl Microbiol 102(4):1026–1032. https://doi.org/10.1111/j.1365-2672.2006.03154.x CrossRefPubMed

15.

Larsen CN, Nielsen S, Kæstel P, Brockmann E, Bennedsen M, Christensen HR, Eskesen DC, Jacobsen BL, Michaelsen KF (2006) Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 60:1284–1293. https://doi.org/10.1038/sj.ejcn.1602450 CrossRefPubMed

16.

Saxelin M, Pessi T, Salminen S (1995) Fecal recovery following oral administration of Lactobacillus strain GG (ATCC 53103) in gelatine capsules to healthy volunteers. Int J Food Microbiol 25:199–203CrossRefPubMed

17.

Oozeer R, Leplingard A, Mater DD, Mogenet A, Michelin R, Seksek I, Marteau P, Doré J, Bresson JL, Corthier G (2006) Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl Environ Microbiol 72(8):5615–5617. https://doi.org/10.1128/AEM.00722-06 CrossRefPubMedPubMedCentral

18.

.Wang R, Chen S, Jin J, Ren F, Li Y, Qiao Z, Wang Y, Zhao L (2015) Survival of Lactobacillus casei strain Shirota in the intestines of healthy Chinese adults. Microbiol Immunol 59(5):268–276. https://doi.org/10.1111/1348-0421.12249 CrossRefPubMed

19.

De Vecchi E, Nicola L, Zanini S, Drago L (2008) In vitro screening of probiotic characteristic of some Italian products. J Chemother 20(3):341–347. https://doi.org/10.1179/joc.2008.20.3.341 CrossRefPubMed

20.

Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S (2014) Modulation of faecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr 144:1787–1796. https://doi.org/10.3945/jn.114.197723 CrossRefPubMed

21.

Balzaretti S, Taverniti V, Guglielmetti S, Fiore W, Minuzzo M, Ngo HN, Ngere JB, Sadiq S, Humphreys PN, Laws AP (2017) A novel rhamnose-rich hetero-exopolysaccharide 1 isolated from Lactobacillus paracasei DG activates THP-1 human monocytic cells. Appl Environ Microbiol 17(3):83. https://doi.org/10.1128/AEM.02702-16 CrossRef

22.

Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, Tagliacarne C, Fiore W, Bellini M, Bertani L, Gambaccini D, Cicala M, Bastianello G, Vecchi M, Pagano I, Barbaro MR, Bellacosa L, Stanghellini V, Barbara G (2017) Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: a pilot randomized clinical trial. United Eur Gastroenterol J 1:1–10. https://doi.org/10.1177/2050640617736478 CrossRef

23.

Balzaretti S, Taverniti V, Rondini G, Marcolegio G, Minuzzo M, Remagni MC, Fiore W, Arioli S, Guglielmetti S (2015) The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration. Front Microbiol 6:952. https://doi.org/10.3389/fmicb.2015.00952 CrossRefPubMedPubMedCentral

24.

D’Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, Castagliuolo I, Sturniolo GC (2011) Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci 56:1178–1187. https://doi.org/10.1007/s10620-010-1384-1 CrossRefPubMed

25.

Turco F, Andreozzi P, Palumbo I, Zito FP, Cargiolli M, Fiore W, Gennarelli N, De Palma GD, Sarnelli G, Cuomo R (2017) Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572). United Eur Gastroenterol J 5(5):715–724. https://doi.org/10.1177/2050640616684398 CrossRef

26.

Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G, Rodino S, D’Amico T, Sacca N, Portincasa P, Capezzuto E, Lattanzio R, Spadaccini A, Fiorella S, Polimeni F, Polimeni N, Stoppino V, Stoppino G, Giorgetti GM, Aiello F, Danese S (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease—a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38:741–751. https://doi.org/10.1111/apt.12463 CrossRefPubMed

27.

Rosania R, Giorgio F, Principi MB, Amoruso A, Monno R, Di Leo A, Ierardi E (2013) Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol 8(2):169–172CrossRefPubMed

28.

Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B, Salvatore U, Nardone G (2017) Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of postinfectious irritable bowel syndrome. BMC Gastroenterol 17(1):53. https://doi.org/10.1186/s12876-017-0605-x CrossRefPubMedPubMedCentral

29.

Drago L, De Vecchi E, Valli M, Nicola L, Lombardi A, Gismondo MR (2002) Colonizzazione intestinale di Lactobacillus casei subsp. casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci e terapia 19(1/2):72–76 (article in Italian)

30.

Arioli S, Koirala R, Taverniti V, Fiore W, Guglielmetti S (2018) Quantitative recovery of viable Lactobacillus paracasei CNCM I-1572 (L. casei DG®) after gastrointestinal passage in healthy adults. Front Microbiol 9:1720. https://doi.org/10.3389/fmicb.2018.01720 CrossRefPubMedPubMedCentral

31.

SSP SGP (2012) Growing curves. http://www.swiss-paediatrics.org/sites/default/files/ recommandations/courbes_de_croissances/pdf/perzentilen_2012_09_15_sgp_i.pdf. Accessed 20 Jun 2017

32.

Lewis SJ, Heaton KW (1997) Stool form as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920–924. https://doi.org/10.3109/00365529709011203 CrossRefPubMed

33.

Szymański H, Chmielarczyk A, Strus M, Pejcz J, Jawień M, Kochan P, Heczko PB (2006) Colonisation of the gastrointestinal tract by probiotic L. rhamnosus strains in acute diarrhoea in children. Dig Liver Dis 38(Suppl 2):S274–S276. https://doi.org/10.1016/S1590-8658(07)60009-7 CrossRefPubMed

34.

Marzotto M, Maffeis C, Paternoster T, Ferrario R, Rizzotti L, Pellegrino M, Dellaglio F, Torriani S (2006) Lactobacillus paracasei A survives gastrointestinal passage and affects the fecal microbiota of healthy infants. Res Microbiol 157(9):857–866. https://doi.org/10.1016/j.resmic.2006.06.007 CrossRefPubMed

35.

Firmesse O, Mogenet A, Bresson JL, Corthier G, Furet JP (2008) Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying microbiota equilibrium as assessed by real-time polymerase chain reaction. J Mol Microbiol Biotechnol 14(1–3):90–99. https://doi.org/10.1159/000106087 CrossRefPubMed

36.

Fujimoto J, Matsuki T, Sasamoto M, Tomii Y, Watanabe K (2008) Identification and quantification of Lactobacillus casei strain Shirota in human feces with strain-specific primers derived from randomly amplified polymorphic DNA. Int J Food Microbiol 126(1–2):210–215. https://doi.org/10.1016/j.ijfoodmicro.2008.05.022 CrossRefPubMed

37.

Ahlroos T, Tynkkynen S (2009) Quantitative strain-specific detection of Lactobacillus rhamnosus GG in human faecal samples by real-time PCR. J Appl Microbiol 106(2):506–514. https://doi.org/10.1111/j.1365-2672.2008.04018.x CrossRefPubMed

38.

Salonen A, de Vos WM (2014) Impact of diet on human intestinal microbiota and health. Annu Rev Food Sci Technol 5:239–262. https://doi.org/10.1146/annurev-food-030212-182554 CrossRefPubMed

39.

Russo F, Clemente C, Linsalata M, Chiloiro M, Orlando A, Marconi E, Chimienti G, Riezzo G (2011) Effects of a diet with inulin-enriched pasta on gut peptides and gastric emptying rates in healthy young volunteers. Eur J Nutr 50(4):271–277. https://doi.org/10.1007/s00394-010-0135-6 CrossRefPubMed

40.

Hojsak I (2017) Probiotics in children: what is the evidence? Pediatr Gastroenterol Hepatol Nutr 20(3):139–146. https://doi.org/10.5223/pghn.2017.20.3.139 CrossRefPubMedPubMedCentral

41.

Allen SJ, Martinez EG, Gregorio GV, Dans LF (2010) Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 10(11):CD003048. https://doi.org/10.1002/14651858.CD003048.pub3 CrossRef

42.

Szajewska H, Skórka A, Ruszczyński M, Gieruszczak-Białek D (2007) Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 25(8):871–881. https://doi.org/10.1111/j.1365-2036.2007.03282.x CrossRefPubMed

Title: Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population
Publication date: 01-12-2019
Published in: European Journal of Nutrition / Issue 8/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-018-1860-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Survival of L. casei DG^® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Carbohydrate nutrition variables and risk of disability in instrumental activities of daily living

Maternal selenium status is profoundly involved in metabolic fetal programming by modulating insulin resistance, oxidative balance and energy homeostasis

Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect

Montmorency tart cherry protects against age-related bone loss in female C57BL/6 mice and demonstrates some anabolic effects

Supplements with purported effects on muscle mass and strength

Differential capability of metabolic substrates to promote hepatocellular lipid accumulation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page